Ambrilia Biopharma Inc. (TSX:AMB) is a biopharmaceutical company developing innovative therapeutics in the fields of oncology and infectious diseases. Ambrilia’s product portfolio includes proprietary mid to early-stage products; an anti-cancer therapeutic peptide (PCK3145), a novel anti-cancer therapy (TVT-Dox), two oncology specialty generics (Octreotide, Goserelin), the first of which is late-stage and value-added, and promising anti-HIV treatments (PPL-100, SPC3). Ambrilia’s product candidates address unmet medical needs in the fields of oncology and infectious diseases where safe and effective therapies are needed, and which represent large market opportunities.
| Contact Details: |
| 1000 chemin du Golf |
| Verdun |
| Quebec |
| H3E 1H4 |
| |
| Tel: | (514) 751-2003 |
| Fax: | (514) 751-2502 |
| Email: | cpanchal@ambrilia.com., rnaudin@ambrilia.com |
| WWW: | www.ambrilia.com/
|
| |
Recent Publications by Ambrilia Biopharma Inc.: |  |
PL-100, a novel HIV-1 protease inhibitor displaying a high genetic barrier to resistance: an in vitro selection study.
The development of new HIV inhibitors with distinct resistance profiles is... | 25th December, 2008
| Ambrilia Biopharma
| J Med Virol. 2008 Dec;80(12):2053-63.
DOI Direct Link |
Animal toxins acting on voltage-gated potassium channels.
Animal venoms are rich natural sources of bioactive compounds, including... | 15th November, 2008
| Ingenierie des peptides a visee therapeutique, ERT 62, Universite de
| Curr Pharm Des. 2008;14(24):2503-18.
|
Effect of Cu2+ on the oxidative folding of synthetic maurotoxin in vitro.
Maurotoxin (MTX) is a 34-mer scorpion toxin cross-linked by four... | 24th September, 2008
| ERT 62 "Ingenierie des proteines", Universite de la Mediterranee-Ambrilia
| J Biomol Struct Dyn. 2008 Aug;26(1):75-82.
|
Binding and internalization of NGR-peptide-targeted liposomal doxorubicin (TVT-DOX) in CD13-expressing cells and its antitumor effects.
In an effort to develop new agents and molecular targets for the treatment... | 13th February, 2008
| Ambrilia Biopharma Inc., Chemin Du Golf, Verdun, Quebec, Canada.
| Anticancer Drugs. 2007 Nov;18(10):1189-200.
DOI Direct Link |
Cloning, expression, purification and functional characterization of recombinant human PSP94.
Human PSP94 (prostate secretory protein of 94 amino acids) is a major... | 27th July, 2007
| Ambrilia Biopharma Inc. 1000, Chemin du Golf Verdun, Canada.
| Protein Expr Purif. 2007 Aug;54(2):193-203. Epub 2007 Mar 23.
DOI Direct Link |
→View more Ambrilia Biopharma Inc. research publications. |
Contact BioPortfolio for a quote for a customised Excel verision of BioCorporate or BioEmail databases.
This page has been viewed 263 times since April 2007, the link to the organisation's website has been followed 43 times
Search for more companies in Verdun
Search for more companies in Quebec
This site uses Thumbshots previews, resources from the NCBI applied. Maps are centred on zip/postcodes and should not be relied upon for exact building locations. Some information on this page has been collected automatically and may not have been verified.BioPortfolio search results for
Ambrilia Biopharma Inc.
